54 related articles for article (PubMed ID: 34022224)
41. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
[TBL] [Abstract][Full Text] [Related]
42. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
43. Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer metastasis and chemotherapeutic drug-induced apoptosis.
Tai CJ; Hsu CH; Shen SC; Lee WR; Jiang MC
J Exp Clin Cancer Res; 2010 Aug; 29(1):110. PubMed ID: 20701792
[TBL] [Abstract][Full Text] [Related]
44. Organization of transcriptional regulatory machinery in nuclear microenvironments: implications for biological control and cancer.
Stein GS; Lian JB; van Wijnen AJ; Stein JL; Javed A; Montecino M; Choi JY; Vradii D; Zaidi SK; Pratap J; Young D
Adv Enzyme Regul; 2007; 47():242-50. PubMed ID: 17363043
[No Abstract] [Full Text] [Related]
45. CSE1L promotes nuclear accumulation of transcriptional coactivator TAZ and enhances invasiveness of human cancer cells.
Nagashima S; Maruyama J; Honda K; Kondoh Y; Osada H; Nawa M; Nakahama KI; Ishigami-Yuasa M; Kagechika H; Sugimura H; Iwasa H; Arimoto-Matsuzaki K; Nishina H; Hata Y
J Biol Chem; 2021 Jul; 297(1):100803. PubMed ID: 34022224
[TBL] [Abstract][Full Text] [Related]
46. CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy.
Jiang MC
Tumour Biol; 2016 Oct; 37(10):13077-13090. PubMed ID: 27596143
[TBL] [Abstract][Full Text] [Related]
47. Regulation of TAZ in cancer.
Zhou X; Lei QY
Protein Cell; 2016 Aug; 7(8):548-61. PubMed ID: 27412635
[TBL] [Abstract][Full Text] [Related]
48. CSE1L/CAS: its role in proliferation and apoptosis.
Behrens P; Brinkmann U; Wellmann A
Apoptosis; 2003 Jan; 8(1):39-44. PubMed ID: 12510150
[TBL] [Abstract][Full Text] [Related]
49. The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine.
Nagashima S; Bao Y; Hata Y
Curr Drug Targets; 2017; 18(4):447-454. PubMed ID: 26758663
[TBL] [Abstract][Full Text] [Related]
50. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
51.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
52.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
